



CIN No. L24232PB1983PLC005426

D.L. No. 1800-OSP, 1804-B

GST No. 03AAACK6458M1ZB

I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LTD.

Regd. Office: 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com

To,

Date: June 10, 2022

The Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
25th Floor, Dalal Street,
Mumbai-400001

Scrip Code: 539997

Sub: Migration of Equity Shares of Company from SME Platform of BSE Limited to Main Board of BSE Limited

Dear Sir/Madam,

We are pleased to inform you that the Company has received the Approval Letter from BSE Limited vide letter reference no. LO/Migration/SC/MIG-TP/86/2022-23 dated June 10, 2022, wherein BSE has approved the Company's application with respect to migration of equity shares of the company from BSE SME platform to BSE Main Board Platform w.e.f June 13, 2022 and the Company will be categorized under the list of 'B' Group Category. (Copy of the same is enclosed).

Kindly take the same on record.

Thanking you,

Yours Faithfully

For Kwality Pharmaceuticals Limited

Gurpreet Kaur

Gurpreet Kaur

Company Secretary & Compliance Officer

M.No. A52091



LO/Migration/SC/MIG-TP/86/2022-23

June 10, 2022

The Company Secretary
Kwality Pharmaceuticals Limited
Majitha Road
Village Nagkalan, Amritsar
Punjab, 143601

Dear Sir/ Madam,

Sub: Migration of Equity Shares of Kwality Pharmaceuticals Limited from BSE SME Platform to BSE Mainboard Platform

We acknowledge the receipt of documents dated June 06, 2022. We have pleasure in advising that effective from **Monday, June 13, 2022**, the equity shares of the Company will be migrated from the BSE SME Platform to BSE Mainboard of the Exchange. We enclose herewith a copy of the Notice No: 20220609-19 dated Thursday, June 09, 2022, issued in this regard to the Trading Members of the Exchange for your information.

1. The company should make a note to quote the relevant code numbers allotted to its securities (as mentioned in the attached notice), while carrying out correspondence in future with the Exchange in respect of matters such as date(s) of closure of its register of members, record date, matters relating to dividend, bonus shares, rights issue, preferential offer, conversion of debentures into equity shares.
2. The Company should submit Corporate Compliances and various other filings through the online listing portal called the Listing Centre. The URL for this portal is <http://listing.bseindia.com>. For further details, please refer to our notice numbers 20130208-6 dated February 08, 2013, and 20130729-25 dated July 29, 2013, available on BSE website.

If you require any further clarification, please feel free to contact Mr. Raghavendra Bhat, on Tel. No. 022-22728915.

Yours faithfully,
For BSE Limited

Sd/-
Rupal Khandelwal
Assistant General Manager

Sd/-
Raghavendra Bhat
Deputy Manager

NOTICES

Notice No.	20220609-19	Notice Date	09 Jun 2022
Category	Company related	Segment	SME
Subject	Migration of Equity Shares of Kwaliti Pharmaceuticals Limited from BSE SME Platform to BSE Mainboard Platform		
Attachments	Annexure I.pdf ; Annexure II.pdf		

Content

Trading Members of the Exchange are hereby informed that effective from **Monday, June 13, 2022**, the equity shares of **Kwaliti Pharmaceuticals Limited** which are already listed under BSE SME Platform will now be migrated & admitted to dealings on the Mainboard Platform in the list of 'B' Group.

<u>Name of the Company</u>	Kwaliti Pharmaceuticals Limited
Registered Office	Majitha Road, Village Nagkalan, Amritsar , Punjab, 143601 Tel. No.- 0183-2774321 / 25 E-mail: cs@kwalitypharma.com Website: www.kwalitypharma.com
Securities	1,03,76,198 Equity Shares of Rs.10/- each fully paid-up
Distinctive numbers	1 to 1,03,76,198
Market Lot	One Share
Scrip Code	539997
Abbreviated Name on BOLT System	KPL
Scrip ID on BOLT System	KPL
ISIN No.	INE552U01010

1. Trading Members may note that as per the guidelines issued by SEBI dated February 16, 2000, securities of the company will only be traded in Dematerialized form. Trades effected in this scrip will be in unit market lot (i.e., one share).

2. The audited financial result of the Company for the year ended March 31, 2022, is enclosed as **Annexure I**.

3. A copy of the shareholding pattern as on June 03, 2022, submitted by the company is enclosed as **Annexure II**.

4. The company's financial year ending is March 31.

5. The address of the Registrar and Transfer Agent of the Company is given below:

Bigshare Services Private Limited

1st Floor, Bharat Tin Works Building,
Opp. Vasant Oasis, Makwana Road, Marol,
Andheri East, Mumbai– 400059, Maharashtra, India

Contact Person: Mr. Ramesh Nair

Telephone No: 022 – 62638200

Email: ipo@bigshareonline.com

6. In case members require any clarifications on the subject matter of this Notice, they may please contact any of the following:

A) At the Company: Ms. Gurpreet Kaur Company Secretary & Compliance Officer	Majitha Road, Village Nagkalan, Amritsar , Punjab, 143601 Tel. No.- 0183-2774321 / 25 E-mail: cs@kwalitlypharma.com W e b s i t e : www.kwalitlypharma.com
B) At the Exchange: Raghavendra Bhat Deputy Manager	Tel.: 022-22728915

Rupal Khandelwal

Assistant General Manager

Thursday, June 09, 2022